Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(60%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
20%
Ph not_applicable
1
20%
Ph phase_2
3
60%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(2)

Detailed Status

Completed2
Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 23 (60.0%)
N/A1 (20.0%)

Trials by Status

active_not_recruiting120%
completed240%
recruiting240%

Recent Activity

3 active trials
Showing 5 of 5
completedphase_2

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

NCT05665348
recruitingnot_applicable

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

NCT06353646
recruitingphase_2

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT05428007
completedphase_1

Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis

NCT03949153
active_not_recruitingphase_2

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

NCT03918252

Clinical Trials (5)

Showing 5 of 5 trials
NCT05665348Phase 2

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

Completed
NCT06353646Not Applicable

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Recruiting
NCT05428007Phase 2

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Recruiting
NCT03949153Phase 1

Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis

Completed
NCT03918252Phase 2

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Active Not Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5